Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD; U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment; Notic ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Tech Xplore on MSN
Programmable metasurface generates dozens of holograms at once
Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...
Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPDU.S. patent to expire in March 2043, including 1,095 days of Patent Term AdjustmentNotice of allowance also recei ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Interesting Engineering on MSN
New US motor slashes internal voltage fluctuations by 90% for electric aircraft
Researchers at the Oak Ridge National Laboratory National Transportation Research Center have designed a ...
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily ...
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results